SHANGHAI – Beijing-based oncology drug developer Beigene Co. Ltd. updated plans for its Nasdaq IPO, seeking to issue 5.5 million American depository shares, representing 71.5 million ordinary shares, priced between $22 to $24 per share, which would bring in $126.5 million at the midpoint, up from the $100 million stated in its initial SEC filing in October.